SCHEMBL15533296

SCHEMBL15533296

NCCOCCOCCOCCOCCOC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 5/20 0.39
GRIN3B O60391 5/20 0.39
GRIN1 Q05586 5/20 0.39
GRIN2A Q12879 5/20 0.39
GRIN2B Q13224 5/20 0.39
GRIN2C Q14957 5/20 0.39
GRIN3A Q8TCU5 5/20 0.39
ALDH1A1 P00352 5/20 0.37
LMNA P02545 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPSR1 Q6W5P4 2/20 0.34
HTT P42858 1/20 0.34
CYP1A2 P05177 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
TSHR P16473 2/20 0.31
SLC22A2 O15244 1/20 0.31
SLC22A1 O15245 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15532220 1.00 GRIN2D (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15532601 1.00 GRIN2D (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15545289 0.91 MEN1 (0.37) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5933135 0.87 GRIN2D (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15545745 0.87 GRIN2D (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15533591 0.80 EPHX2 (0.45) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL16682526 0.80 EPHX2 (0.44) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL21997787 0.80 MEN1 (0.44) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL15532934 0.80 MEN1 (0.44) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL12687856 0.80 MEN1 (0.44) ALDH1A1LMNAMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same YALE UNIVERSITY 2016-01-28 US disclosed
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same YALE UNIVERSITY 2016-01-28 US disclosed
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same YALE UNIVERSITY 2016-01-28 US disclosed
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY 2015-04-30 US disclosed
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY 2015-04-30 US disclosed
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY 2015-04-30 US disclosed
EP-2846784-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME Yale University (US) 2015-03-18 EP disclosed
WO-2013170147-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY (US) 2013-11-14 WO disclosed
WO-2013170147-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY (US) 2013-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME PSMG3, ERAP1, SMURF2 GRIN2D 4831/4885GRIN3B 4678/4885GRIN1 4684/4885
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same AR, SHBG, PSMG3 GRIN2D 4662/4885GRIN3B 4154/4885GRIN1 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.